Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting Data suggest favorable pharmacologic and pharmacokinetic profiles of Entera’s Oral PTH formulation with a flexible oral dosing

  Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting   Data suggest favorable pharmacologic and pharmacokinetic profiles of Entera’s Oral PTH formulation with a flexible oral

JERUSALEM, Israel and BOSTON , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley , CEO, and Dr. Phillip Schwartz , President of R&D, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:00 am Eastern

JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:00 am Eastern

Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented in Q3 2019. Appointed Adam Gridley as Chief Executive Officer Conference call and live webcast

Conference Call Scheduled for 8:30am ET / 1:30pm BST JERUSALEM , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before the U.S.

JERUSALEM, Israel , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip Schwartz , Ph.D., former CEO of Entera since the Company’s inception in 2010, will continue with the

JERUSALEM , July 02, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three different

Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical analysis are ongoing, with results expected to be presented in 2H 2019. Appointed Dana Yaacov-Garbeli, CPA, as interim

Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosis Entered into research collaboration and license agreement with Amgen , potential for up to $270 million in milestone payments, Amgen’s exercise of options to select additional programs and